What is BioCAPTURE

The goal of BioCAPTURE

Psoriasis is an inflammatory disease in which red, scaly patches are visible on the skin. In a substantial part of patients, the joints are also inflamed. When the disease is extensive, some patients are eligible for biologics. Biologics are drugs that are usually given to patients via injections. Examples are: etanercept (ao Enbrel), adalimumab (Humira), infliximab (ao Remicade), ustekinumab (Stelara), secukinumab (Cosentyx), ixekizumab (Taltz), brodalumab (Kyntheum) and guselkumab (Tremfya).

In the BioCAPTURE network, data is collected from psoriasis patients who are treated with  biologics. These data from practice, also known as real world evidence, provide different information than findings from the early randomized trials (RCTs), which are always performed before a drug is marketed. In such RCTs, a relatively healthy population is often investigated for a limited duration. Data from the BioCAPTURE show how well the treatments work in daily practice, where people often also suffer from other disorders and use other medication. Because the BioCAPTURE registry is a long-term project, it also provides insight into the safety of biologics if they are given for many years in succession. The ultimate goal of BioCAPTURE is to generate data that ensures that the right biologic is given to a patient at the right time, with as much effect, and as few side effects, as possible.

What is BioCAPTURE?

BioCAPTURE is a network of dermatology departments of 17 Dutch hospitals. The dermatology department of the Radboudumc coordinates this research. Data from patients treated with biologics in daily practice are collected in a structured, prospecitve way.

Which data is collected in BioCAPTURE?
In general, data is collected that is also normally recorded by doctors in daily practice, such as disease severity, dosages of medication, and side effects. This data forms the core of the BioCAPTURE registry. In addition, questionnaires are sent to patients to measure quality of life, satisfaction with medication, cost effectiveness and the expectations that patients have of treatments. Of note, measuring quality of life through a DLQI questionnaire is often part of usual practice.More specifically, the data collection looks like this:
During each visit:


Disease activity: PASI score (Psoriasis Area and Severity Index), VAS severity (a straight line with two opposite claims about disease severity  at both extremes filled in by patients), PGA (physician global assessment, a global estimate of disease severity by physicians)

Side effects

Medication and dosage changes

In the first treatment year: questionnaires are sent every 3 months. After the first year: questionnaires are sent once a year: 
DLQI (Dermatology Life Quality Index)
TSQM (Treatment Satistfaction Questionnaire for Medication)
EQ-5D (EuroQol 5D)
SF-36 (Short Form-36 survey)
PBI (Patient Benefit Index) (in Radboudumc)
Cost-effectiveness questionnaires

The BioCAPTURE network: past and present

BioCAPTURE is an acronym for: Continuous Assessment of Psoriasis Treatment Use Registry with Biologics. It was set up in 2005 by dermatologists and researchers at the Radboudumc in Nijmegen. The network now consists of the following centers:

Radboudumc Nijmegen, Ziekenhuisgroep Twente locatie Almelo, Ziekenhuisgroep Twente locatie Hengelo, Ziekenhuis Gelderse Vallei Ede, Gelre ziekenhuizen Apeldoorn,  St. Anna Ziekenhuis Geldrop, Maxima Medisch Centrum Eindhoven/Veldhoven, Slingeland Ziekenhuis Doetinchem, Jeroen Bosch Ziekenhuis Den Bosch, St. Antonius ziekenhuis Nieuwegein en Woerden, Rijnstate Ziekenhuis Arnhem, Catharina Ziekenhuis Eindhoven, Bernhoven ziekenhuis Uden, Amphia ziekenhuis Breda, Universitair Medisch Centrum Utrecht, Maastricht UMC, Canisius Wilhelmina Ziekenhuis (CWZ) Nijmegen, Zuyderland MC Sittard/Heerlen, Bravis ziekenhuis Bergen op Zoom, Erasmus ziekenhuis Rotterdam, SKB Winterswijk.